Physician profile
Daniel K Kim
NPI 1346349727
$2,730.92
in general payments reported to CMS, 2019-2025
22 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $104 · 2021: $602 · 2022: $202 · 2023: $212 · 2024: $188 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $449.68 | 2022-2025 | Hydrus Microstent, Tryptyr, Voyager Dslt |
| Biotissue Holdings INC. | $374.36 | 2025 | |
| Mallinckrodt Hospital Products INC. | $316.55 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.74 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $236.84 | 2019-2023 | Cequa |
| Allergan, INC. | $173.32 | 2019-2022 | |
| Amgen INC. | $128.52 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $123.17 | 2023-2024 | Tecnis Iol, Veritas Vision System |
| Glaukos Corporation | $108.42 | 2021 | |
| Bausch & Lomb Americas INC. | $102.64 | 2025 | Vyzulta, Miebo |
| Omeros Corporation | $71.37 | 2020 | |
| Novartis Pharmaceuticals Corporation | $70.39 | 2022-2023 | |
| Dompe US, INC. | $64.97 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $63.82 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $50.97 | 2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $48.07 | 2023 | |
| Shire North American Group INC | $21.18 | 2019 | |
| Oyster Point Pharma, INC. | $17.30 | 2022 | |
| Horizon Therapeutics Plc | $16.60 | 2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $14.75 | 2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Janssen Pharmaceuticals, INC | $14.50 | 2020 | |
| Abbvie INC. | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.